Quick Answer
Nuvectis Pharma, Inc. reported Stockholders Equity of $18.41 million for the year ending 2025.
- Nuvectis Pharma, Inc. showed an increase of +89.6% in Stockholders Equity from 2024 to 2025.
- This data is from Nuvectis Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$33.0 thousand | Q2 2021: -$4.40 million | Q3 2021: -$8.93 million | Q1 2022: $14.56 million | Q2 2022: $11.50 million | Q3 2022: $20.37 million | Q1 2023: $12.27 million | Q2 2023: $20.33 million | Q3 2023: $16.69 million | Q1 2024: $14.02 million | Q2 2024: $12.53 million | Q3 2024: $10.99 million | Q1 2025: $20.95 million | Q2 2025: $16.87 million | Q3 2025: $24.01 million.
- Over the full 6 years of available data (2020 to 2025), Nuvectis Pharma, Inc.'s Stockholders Equity has grown by 184,230.0%.
- Historical annual values: Fiscal year 2025: $18.41 million | Fiscal year 2024: $9.71 million | Fiscal year 2023: $12.20 million | Fiscal year 2022: $14.22 million | Fiscal year 2021: -$11.01 million | Fiscal year 2020: -$10.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: